Jill Broadfoot

Jill Broadfoot

DirectorataTYR Pharma· In proxies 2022–2025

Pay in FY2025+76% from the year before · aTYR Pharma stock -78.4% the same year

Jill Broadfoot was paid $1.3M in FY2025 (Dec), up 76%. aTYR Pharma stock fell 78.4% that year.

Pay$100 in the stock at the end of FY22 → $36
Pay is from the Summary Compensation Table of each aTYR Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cue BiopharmaPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. aTYR PharmaPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role -98%
  3. Talphera, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Angiocrine Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Otonomy, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?